Physician profile
Kendall From, JR.
NPI 1467445304
$1,202.18
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $320 · 2021: $82.69 · 2022: $15.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $254.12 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $237.06 | 2019-2020 | |
| Akebia Therapeutics INC | $183.09 | 2019-2021 | |
| Amgen INC. | $120.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $100.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $88.36 | 2019 | |
| Mallinckrodt Enterprises LLC | $36.80 | 2019 | |
| Novo Nordisk INC | $25.83 | 2020 | |
| Vifor Pharma, INC. | $23.79 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $19.38 | 2019 | |
| Aurinia Pharma U.S., INC. | $17.96 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.30 | 2020 | |
| Sanofi Pasteur INC. | $17.03 | 2021 | |
| Pfizer INC. | $15.83 | 2022 | |
| Opko Pharmaceuticals, LLC | $15.27 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $14.91 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.45 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall From listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.